首页 > 新闻 > 正文

running man

People with HIV at higher risk of COVID reinfection: CDC_我的网站

A | People with HIV are at increased risk of being reinfected with the virus that causes COVID-19, according to new federal data.Researchers from the Centers for Disease Control and Prevention and the Chicago Department of Public Health followed adult residents in Chicago from their first reported infection from March 2020 through the end of May 2022, according to the report published Wednesday by the CDC.The team compared COVID test laboratory data and COVID vaccine administration data to Chicago's Enhanced HIV/AIDS Reporting System.About 5% experienced reinfection among more than 453,000 Chicago residents who tested positive for the virus.Rates of reinfection were higher among people with HIV (6.7%) than among people without HIV (5.2%).People with HIV are more likely to have completed a primary COVID vaccine series plus a booster before their reinfection -- 31.8% versus 27% for those without HIV.Reinfection rates were consistently higher throughout the pandemic for people with HIV and were highest during the original omicron variant phase, according to the report."Understanding if persons with HIV have a higher risk for SARS-CoV-2 reinfection may help tailor future COVID-19 public health guidance," the authors wrote. "[Persons with HIV] should follow the recommended COVID-19 vaccine schedule, including booster doses, to avoid SARS-CoV-2 reinfections."Those who were reinfected were more likely to be male, older and Black or African American compared to those without HIV, the study found.People with HIV were also less likely to have been unvaccinated at the time of their first infection compared to people without HIV.The report notes the findings are a reminder about the risks of reinfection for those who are immunocompromised.HIV can weaken the immune system, infecting and destroying CD4 cells, which causes the white blood cell count to drop and compromises the immune system.This means that people with HIV are susceptible to COVID infection especially those who are not on antiretroviral therapy (ART).ART is a combination of drugs that suppresses a person's viral load until HIV Is virtually undetectable. The ability of ART to control viral replication has been shown to greatly improve immune system function, studies show."Evaluating the association between HIV infection and SARS-CoV-2 reinfections using surveillance data can help strengthen public health recommendations including the need for extra doses as part of a primary series, booster doses of vaccine, and optimized ART in [persons with HIV]," the authors wrote. "Tailored guidance and prevention messaging for [persons with HIV] can help reduce the elevated risk we identified in this analysis and limit continued SARS-CoV-2 transmission."。

B | 　　在“四轮”智能电动后，下一场关于机器人的产业竞争在汽车业愈演愈烈。8月24日当天，包括小鹏、零跑和蔚来在内的三家新势力车企，密集释放了各自进入具身智能机器人赛道的相关信息。　　8月24日，小鹏集团官方宣布，小鹏机器人业务完成首轮超9亿美元融资，投后估值超63亿美元（约430亿元人民币），刷新中国具身智能行业单轮私募股权融资纪录。

C | 　　“小鹏人形机器人IRON计划在2026年底进入量产阶段，从小鹏的门店和园区开始落地商业场景应用，并于2027年面向中国及海外市场正式上市和交付。”小鹏集团表示，通过本轮融资，小鹏机器人业务获得清晰的市场化估值，也将加速小鹏机器人量产及小鹏物理AI模型的研发迭代，推动高阶通用人形机器人迈向全球商业化应用新阶段。“本轮募集资金主要用于小鹏机器人业务的软硬件研发、物理AI模型训练迭代、高质量数据采集、全链条量产基地建设及全球商业化拓展。”　　同日，零跑汽车管理层在2026年中期业绩会上表示，新能源车企，尤其是具备全域自研能力的新能源车企，是最具备做具身智能机器人的企业之一。针对市场关注的机器人业务进展，零跑汽车确认，“公司对此已有规划，机器人相关信息不久后将对外披露。”　　跃跃欲试的还有蔚来汽车。8月24日市场消息称，蔚来智驾负责人任少卿创立具身智能公司，蔚来将对其进行战略投资。对此，接近蔚来管理层的业内人士向财联社记者表示，蔚来长期关注AI前沿技术，以自主研发与开放合作并重的方式进行产业布局。近年来，蔚来在芯片、操作系统等关键技术领域持续投入并取得关键进展，同时通过战略合作、产业协同等方式围绕具身智能、算法模型、智能硬件、新能源与算力基础设施等方向持续支持创新企业发展。　　至此，理想、小鹏、蔚来及零跑汽车四家头部新造车企业，已齐聚智能机器人赛道。　　相比新势力，传统主机厂的脚步更快。8月中旬，广汽集团孵化的人形机器人公司广东慧仑科技宣布完成超亿元融资，由中车国创基金、招银国际、四川科创等机构联合投资。几乎同一时期，广汽资本领投了机器人力传感器企业蓝点触控数亿元D轮融资。此外，中国一汽董事长、党委书记邱现东在8月21日的中国一汽2026年科技大会上，明确将突破L4自动驾驶技术、具身智能机器人技术等十大重点技术任务。　　“我们自主设计开发了全部的原生硬件平台和软件体系。

D | 整个（机器人）供应链企业也有 85%以上与当前的小鹏汽车重合。所以我们非常相信，最终小鹏的机器人成本竞争力在行业里面肯定是领先的。”小鹏集团董事长何小鹏在公司2026年中期业绩会上表示，当前国内机器人BOM成本通常为汽车的2.5-3倍，而小鹏IRON身定位在通用类型集成，“我相信它具有非常广阔的定价空间，其硬件毛利会大幅高于当前我们汽车业务的毛利。”　　“车企布局人形机器人，具备成本、效率、技术的三重优势。”在业内人士看来，汽车产业成熟的供应链体系、制造工艺与成本控制能力，正加速向机器人领域迁移，这种跨产业协同有望推动减速器、伺服系统等关键零部件降本提质，在提升整机可靠性的同时，进一步放大产业链整体需求，“人形机器人正在被车企视为智能化能力的下一块试验田。

E | ”　　摩根士丹利研报显示，到2036年全球人形机器人保有量将达2440万台，2050年升至10亿台，对应市场年收入达7.5万亿美元；中国2050年累计保有量约3亿台，占全球总量约30%。人形机器人产业有望逐步从B端工业场景向C端消费市场渗透，成为下一个万亿级新兴赛道。　　“未来能够持续生存的汽车企业大多会进入机器人行业。